SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following a promising earnings report, which highlighted a substantial new credit facility and several Material Transfer Agreements, notably one focused on oncology. The community is optimistic about the diversification potential of its Matrix-M adjuvant in new therapeutic areas, with discussions also circling around short interest and the strategic influence of major shareholders.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending after strong earnings and bullish guidance have validated confidence in the AI sector, yet its muted immediate price reaction is fueling community debate over market manipulation and the AI boom's future, further complicated by ongoing chip export concerns to China.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy Enterprises is experiencing a significant downturn following a substantial earnings and revenue miss, leading to widespread investor frustration and questions about management's credibility, while some observers cautiously eye the sharp pullback as a potential buying opportunity given the broader demand for battery energy storage systems.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending following its strong Q4 earnings beat, robust revenue growth, and key strategic developments including a major European quantum network deployment and a significant U.S. defense contract, fueling polarized community discussions about its high valuation and future leadership amid continued losses.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius (CELH) is surging after a strong earnings report exceeded expectations and positive comments from a recent conference revealed significant shelf-space gains for its brands, particularly Alani Nu, and strong international growth potential. While bulls celebrate robust performance and anticipate continued expansion, community discussions also include concerns over the CEO's communication style and speculative theories about a potential PepsiCo buyout.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending after exceeding earnings expectations and announcing a substantial new share buyback program, leading many in the community to view the stock as deeply undervalued and oversold despite broader market concerns about AI disruption to the software sector.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending after reporting strong revenue and customer growth in its latest quarter, with the market increasingly noting its dominance as China's intense coffee price war appears to be easing. The community is weighing rapid store expansion and perceived undervaluation against lingering concerns over profit margins and the ongoing desire for a US market relisting.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum Inc. is experiencing intense debate following its recent financial report, where discussions of significant losses and missed revenue estimates clash with bullish forward-looking statements about strong customer engagements, government partnerships, and its strategic dual-platform approach in the high-stakes quantum computing sector.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk (TTD) is seeing intense volatility after its Q4 earnings beat was overshadowed by weaker-than-anticipated Q1 guidance, sparking a major sell-off. While many in the community view the sharp decline as an overreaction and a generational buying opportunity given strong fundamentals and planned share buybacks, others express deep concern over decelerating growth and management's strategy amid competitive pressures in the ad tech sector.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending following a strong Q4 '25 earnings beat and robust cash flow, yet investor attention is keenly focused on management's limited disclosures regarding the AUR200 pipeline, driving significant speculation about a potential buyout by a larger pharmaceutical company eager to capitalize on both its commercialized lupus nephritis drug and its promising autoimmune pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ESLA news already out? Nasdaq: ESLA today announced its STARLIGHT-1 phase I result will be orally presented at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). 
The presentation will highlight clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). 
Estrella’s late-breaking abstract will be available on February 4, 2026, at 12:00 a.m. CT, via the conference website at www.tandemmeetings.com. 
Details of the Late-Breaking Oral Presentation: 
· Final Paper Number: LBA-1 
· Abstract ID &amp; Title: 29644: Phase-1 Study of CD19-ARTEMIS T Cells (EB103) in Patients with Aggressive B-Cell 
 
· Session Date/Time: Saturday, February 7, 2026, 3:15 p.m. MST 
 
· Presenting Author: Naseem Esteghamat, MD MS

The Tandem Meetings are a premier event in the evolving hematopoietic cell transplantation (HCT) and cellular therapy field. Through the scientific program, attendees gain access to the latest scientific updates, new technologies and innovative products I hematopoietic cell transplantation and cellular therapy

Tandemmeetings

Tandem Meetings Home

StockTwits Web

Estrella Biopharma Inc

 news already out? Nasdaq: ESLA today announced its STARLIGHT-1 phase I result will be orally presented at the 2026 ASTCT & CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood & Marrow Transplant Research). 
The presentation will highlight clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). 
Estrella’s late-breaking abstract will be available on February 4, 2026, at 12:00 a.m. CT, via the conference website at 

. 
Details of the Late-Breaking Oral Presentation: 
· Final Paper Number: LBA-1 
· Abstract ID & Title: 29644: Phase-1 Study of CD19-ARTEMIS T Cells (EB103) in Patients with Aggressive B-Cell 
 
· Session Date/Time: Saturday, February 7, 2026, 3:15 p.m. MST 
 
· Presenting Author: Naseem Esteghamat, MD MS